...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Endocrine journal >Continuous subcutaneous insulin infusion combined with liraglutide reduced glycemic variability and oxidative stress in type 2 diabetes mellitus: a study based on the flash glucose monitoring system
【24h】

Continuous subcutaneous insulin infusion combined with liraglutide reduced glycemic variability and oxidative stress in type 2 diabetes mellitus: a study based on the flash glucose monitoring system

机译：连续皮下胰岛素输注联合Liraglutide降低2型糖尿病的血糖变异性和氧化应激：基于闪光葡萄糖监测系统的研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We aimed to explore the use of the flash glucose monitoring (FGM) system in hospitalized newly diagnosed type 2 diabetes mellitus (T2DM) patients and to evaluate a new combination therapy of continuous subcutaneous insulin infusion (CSII) with or without liraglutide. This was an open-label, randomized study that was conducted in 60 newly diagnosed T2DM patients. The patients were randomized to receive either CSII (n = 30) or CSII + liraglutide (n = 30). The FGM system was used to assess the glycemic control and glycemic variability (GV) indices for 2 weeks. Mean blood glucose concentration (MBG), estimated hemoglobin A1c (HbA1c), and measures of GV, including the standard deviation of the mean glucose (SD), coefficient of variation (CV), interquartile range (IQR), mean amplitude of glycemic excursions (MAGE), largest amplitude of glycemic excursions (LAGE), and mean of daily difference (MODD) were compared between the two groups. Two oxidative stress biomarkers, 4-hydroxynonenal (4-HNE) and 8-hydroxydeoxyguanosine (8-OHdG), were measured before and after treatment. The estimated HbA1c and MBG decreased in both groups, especially the CSII + liraglutide group. SD, IQR, LAGE, and MODD were significantly lower in the CSII + liraglutide group than in the CSII group (all p 0.05); there was no difference in CV or MAGE (p 0.05). Similarly, the 4-HNE and 8-OHdG levels were significantly lower in the CSII + liraglutide group (p 0.05). Our findings suggest that CSII with liraglutide was superior to CSII monotherapy in improving glycemic control and glycemic variability and in decreasing oxidative stress markers. Flash glucose monitoring can successfully provide ambulatory glucose profile data in the real world.
机译：我们旨在探讨使用闪光葡萄糖监测（FGM）系统在住院治疗的2型糖尿病患者（T2DM）患者中，并评估连续皮下胰岛素输注（CSII）的新组合治疗，无论是否有丽格列德。这是60名新诊断的T2DM患者进行的开放标签，随机研究。患者随机地接受CSII（n = 30）或CSII + Liraglutide（n = 30）。 FGM系统用于评估血糖控制和血糖变异性（GV）指数2周。平均血糖浓度（MBG），估计的血红蛋白A1C（HBA1C）和GV的衡量标准偏差，包括平均葡萄糖（SD），变异系数（CV），血糖偏移的平均幅度（IQR），平均振幅（IQR），平均血糖偏移的标准偏差（法师），比较两组之间的血糖偏移（鼠标）的最大振幅和日常差异（MODD）的平均值。在处理之前和之后测量两种氧化应激生物标志物，4-羟基诺（4-HNE）和8-羟基氧基胍（8-OHDG）。估计的HBA1C和MBG在两组中减少，特别是CSII + Liraglutide组。 CSII + Liraglutide组在CSII组中显着降低SD，IQR，鼠李和MODD（所有P <0.05）; CV或法师没有差异（p> 0.05）。类似地，CSII +黎射蛋白质组的4-HNE和8-OHDG水平显着较低（P <0.05）。我们的研究结果表明，CSII与Liraglutide优于CSII单疗法，从而改善血糖控制和血糖变异性以及降低氧化应激标记物。闪存血糖监测可以在现实世界中成功提供汽车血糖概况数据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号